Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 30

1.

Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model.

Waugh KA, Leach SM, Moore BL, Bruno TC, Buhrman JD, Slansky JE.

J Immunol. 2016 Aug 15;197(4):1477-88. doi: 10.4049/jimmunol.1600589. Epub 2016 Jul 1.

2.

Identification of shared TCR sequences from T cells in human breast cancer using emulsion RT-PCR.

Munson DJ, Egelston CA, Chiotti KE, Parra ZE, Bruno TC, Moore BL, Nakano TA, Simons DL, Jimenez G, Yim JH, Rozanov DV, Falta MT, Fontenot AP, Reynolds PR, Leach SM, Borges VF, Kappler JW, Spellman PT, Lee PP, Slansky JE.

Proc Natl Acad Sci U S A. 2016 Jul 19;113(29):8272-7. doi: 10.1073/pnas.1606994113. Epub 2016 Jun 15.

3.

Tolerance of Tumor-Specific T cells in Melanoma Metastases.

Waugh KA, Leach SM, Slansky JE.

J Clin Cell Immunol. 2016 Apr;7(2). pii: 409. Epub 2016 Apr 14. No abstract available.

4.

Flow Cytometric Analysis of Mononuclear Phagocytes in Nondiseased Human Lung and Lung-Draining Lymph Nodes.

Desch AN, Gibbings SL, Goyal R, Kolde R, Bednarek J, Bruno T, Slansky JE, Jacobelli J, Mason R, Ito Y, Messier E, Randolph GJ, Prabagar M, Atif SM, Segura E, Xavier RJ, Bratton DL, Janssen WJ, Henson PM, Jakubzick CV.

Am J Respir Crit Care Med. 2016 Mar 15;193(6):614-26. doi: 10.1164/rccm.201507-1376OC.

5.

Targeting Transcriptional Regulators of CD8+ T Cell Dysfunction to Boost Anti-Tumor Immunity.

Waugh KA, Leach SM, Slansky JE.

Vaccines (Basel). 2015 Sep 17;3(3):771-802. doi: 10.3390/vaccines3030771. Review.

6.

Dendritic cell subsets require cis-activation for cytotoxic CD8 T-cell induction.

Desch AN, Gibbings SL, Clambey ET, Janssen WJ, Slansky JE, Kedl RM, Henson PM, Jakubzick C.

Nat Commun. 2014 Aug 19;5:4674. doi: 10.1038/ncomms5674.

7.

Improving antigenic peptide vaccines for cancer immunotherapy using a dominant tumor-specific T cell receptor.

Buhrman JD, Jordan KR, Munson DJ, Moore BL, Kappler JW, Slansky JE.

J Biol Chem. 2013 Nov 15;288(46):33213-25. doi: 10.1074/jbc.M113.509554. Epub 2013 Oct 8.

8.

Mimotope vaccine efficacy gets a "boost" from native tumor antigens.

Buhrman JD, Slansky JE.

Oncoimmunology. 2013 Apr 1;2(4):e23492.

9.

Augmenting antitumor T-cell responses to mimotope vaccination by boosting with native tumor antigens.

Buhrman JD, Jordan KR, U'ren L, Sprague J, Kemmler CB, Slansky JE.

Cancer Res. 2013 Jan 1;73(1):74-85. doi: 10.1158/0008-5472.CAN-12-1005. Epub 2012 Nov 16.

10.

Influence of human immune cells on cancer: studies at the University of Colorado.

Bruno TC, French JD, Jordan KR, Ramirez O, Sippel TR, Borges VF, Haugen BR, McCarter MD, Waziri A, Slansky JE.

Immunol Res. 2013 Mar;55(1-3):22-33. doi: 10.1007/s12026-012-8346-y. Review.

11.

Improving T cell responses to modified peptides in tumor vaccines.

Buhrman JD, Slansky JE.

Immunol Res. 2013 Mar;55(1-3):34-47. doi: 10.1007/s12026-012-8348-9. Review.

12.
13.

TCR hypervariable regions expressed by T cells that respond to effective tumor vaccines.

Jordan KR, Buhrman JD, Sprague J, Moore BL, Gao D, Kappler JW, Slansky JE.

Cancer Immunol Immunother. 2012 Oct;61(10):1627-38. Epub 2012 Feb 21.

14.

Tumor-associated antigen expressing Listeria monocytogenes induces effective primary and memory T-cell responses against hepatic colorectal cancer metastases.

Olino K, Wada S, Edil BH, Pan X, Meckel K, Weber W, Slansky J, Tamada K, Lauer P, Brockstedt D, Pardoll D, Schulick R, Yoshimura K.

Ann Surg Oncol. 2012 Jul;19 Suppl 3:S597-607. doi: 10.1245/s10434-011-2037-0. Epub 2011 Oct 7.

15.

Elevated tumor-associated antigen expression suppresses variant peptide vaccine responses.

Kemmler CB, Clambey ET, Kedl RM, Slansky JE.

J Immunol. 2011 Nov 1;187(9):4431-9. doi: 10.4049/jimmunol.1101555. Epub 2011 Sep 21.

16.

Gene expression profiling identifies inflammation and angiogenesis as distinguishing features of canine hemangiosarcoma.

Tamburini BA, Phang TL, Fosmire SP, Scott MC, Trapp SC, Duckett MM, Robinson SR, Slansky JE, Sharkey LC, Cutter GR, Wojcieszyn JW, Bellgrau D, Gemmill RM, Hunter LE, Modiano JF.

BMC Cancer. 2010 Nov 9;10:619. doi: 10.1186/1471-2407-10-619.

17.

The Goldilocks model for TCR-too much attraction might not be best for vaccine design.

Slansky JE, Jordan KR.

PLoS Biol. 2010 Sep 14;8(9). pii: e1000482. doi: 10.1371/journal.pbio.1000482. No abstract available.

18.

Peptide vaccines prevent tumor growth by activating T cells that respond to native tumor antigens.

Jordan KR, McMahan RH, Kemmler CB, Kappler JW, Slansky JE.

Proc Natl Acad Sci U S A. 2010 Mar 9;107(10):4652-7. doi: 10.1073/pnas.0914879107. Epub 2010 Jan 26. Erratum in: Proc Natl Acad Sci U S A. 2010 Mar 9;107(10):4788-9.

19.

Vaccination of mice with baculovirus-infected insect cells expressing antigenic proteins.

Jordan KR, Crawford F, Kappler JW, Slansky JE.

Curr Protoc Immunol. 2009 Apr;Chapter 2:Unit 2.15. doi: 10.1002/0471142735.im0215s85.

20.

Age-dependent tolerance to an endogenous tumor-associated antigen.

McWilliams JA, Sullivan RT, Jordan KR, McMahan RH, Kemmler CB, McDuffie M, Slansky JE.

Vaccine. 2008 Mar 28;26(15):1863-1873. doi: 10.1016/j.vaccine.2008.01.052. Epub 2008 Feb 20.

Supplemental Content

Loading ...
Support Center